Propanc Biopharma Announces Publication Of Evaluation Of Recombinant Trypsinogen And Chymotrypsinogen In Peer-Reviewed Journal Microbial Cell Factories
Propanc Biopharma, Inc. (NASDAQ:PPCB) ("Propanc" or the "Company"), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer,
Propanc published research about two proteins in a science journal, showing their work to other scientists. When companies share research results publicly, it can help people understand what the company is working on and whether the science looks promising.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.